WST West Pharmaceutical Services Inc

Price (delayed)

$404.81

Market cap

$29.95B

P/E Ratio

57.75

Dividend/share

$0.68

EPS

$7.01

Enterprise value

$29.69B

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, ...

Highlights
The net income has soared by 82% YoY and by 23% from the previous quarter
WST's EPS has surged by 81% year-on-year and by 23% since the previous quarter
The stock's price to earnings (P/E) is 23% more than its 5-year quarterly average of 46.8 and 2.2% more than its last 4 quarters average of 56.5

Key stats

What are the main financial stats of WST
Market
Shares outstanding
73.98M
Market cap
$29.95B
Enterprise value
$29.69B
Valuations
Price to earnings (P/E)
57.75
Price to book (P/B)
14.7
Price to sales (P/S)
11.88
EV/EBIT
47.15
EV/EBITDA
39.88
EV/Sales
11.77
Earnings
Revenue
$2.52B
EBIT
$629.7M
EBITDA
$744.5M
Free cash flow
$283.6M
Per share
EPS
$7.01
Free cash flow per share
$3.83
Book value per share
$27.53
Revenue per share
$34.09
TBVPS
$37.78
Balance sheet
Total assets
$2.93B
Total liabilities
$900.9M
Debt
$319.4M
Equity
$2.03B
Working capital
$1B
Liquidity
Debt to equity
0.16
Current ratio
3.13
Quick ratio
2.24
Net debt/EBITDA
-0.34
Margins
EBITDA margin
29.5%
Gross margin
39.4%
Net margin
20.6%
Operating margin
23.9%
Efficiency
Return on assets
18.8%
Return on equity
27.9%
Return on invested capital
32.8%
Return on capital employed
25.6%
Return on sales
25%
Dividend
Dividend yield
0.17%
DPS
$0.68
Payout ratio
9.7%

WST stock price

How has the West Pharmaceutical Services stock price performed over time
Intraday
-0.64%
1 week
-0.57%
1 month
-10.54%
1 year
38.93%
YTD
42.89%
QTD
-4.65%

Financial performance

How have West Pharmaceutical Services's revenue and profit performed over time
Revenue
$2.52B
Gross profit
$992.7M
Operating income
$602.2M
Net income
$519.2M
Gross margin
39.4%
Net margin
20.6%
The net income has soared by 82% YoY and by 23% from the previous quarter
WST's operating income has soared by 79% YoY and by 22% from the previous quarter
The gross profit has grown by 50% YoY and by 14% from the previous quarter
WST's net margin is up by 40% year-on-year and by 13% since the previous quarter

Growth

What is West Pharmaceutical Services's growth rate over time

Valuation

What is West Pharmaceutical Services stock price valuation
P/E
57.75
P/B
14.7
P/S
11.88
EV/EBIT
47.15
EV/EBITDA
39.88
EV/Sales
11.77
WST's EPS has surged by 81% year-on-year and by 23% since the previous quarter
The stock's price to earnings (P/E) is 23% more than its 5-year quarterly average of 46.8 and 2.2% more than its last 4 quarters average of 56.5
The price to book (P/B) is 96% higher than the 5-year quarterly average of 7.5 and 24% higher than the last 4 quarters average of 11.9
WST's equity is up by 27% year-on-year and by 11% since the previous quarter
The P/S is 95% above the 5-year quarterly average of 6.1 and 21% above the last 4 quarters average of 9.8
West Pharmaceutical Services's revenue has increased by 30% YoY and by 8% from the previous quarter

Efficiency

How efficient is West Pharmaceutical Services business performance
WST's return on invested capital has surged by 59% year-on-year and by 17% since the previous quarter
West Pharmaceutical Services's ROE has soared by 50% YoY and by 16% from the previous quarter
The company's return on assets has surged by 50% YoY and by 17% QoQ
WST's return on sales is up by 38% year-on-year and by 13% since the previous quarter

Dividends

What is WST's dividend history
DPS
$0.68
Dividend yield
0.17%
Payout ratio
9.7%
Recent dividends

Financial health

How did West Pharmaceutical Services financials performed over time
WST's total assets is up by 23% year-on-year and by 7% since the previous quarter
The total liabilities has increased by 15% year-on-year
WST's debt is 84% smaller than its equity
WST's equity is up by 27% year-on-year and by 11% since the previous quarter
The debt to equity has contracted by 20% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.